Janux Therapeutics, Inc.

JANXNASDAQHealthcare● Active

$13.51

+$0.15(+1.12%)

Market Cap$823898623

P/E Ratio—

52W High$35.34

52W Low$12.12

Avg Volume1.0M

Open$13.44

Beta2.52

Overview

Janux Therapeutics, Inc. (JANX) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · JANX · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

Janux Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

JANX insider buying and selling by quarter

JANX insider selling · JANX insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

3.8M1.9M0

2024 Q2

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q4

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · JANX ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

JANX executive sell shares · JANX board member insider trading · JANX insider trading SEC filing

Showing 63 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Jun 2, 2026	Doyle Janeen Noel Chief Corp. & Bus. Dev. Ofcr	Sale	4,059	$14.03	$57K	75,941	Form 4
May 11, 2026	Dobek Maria Vice President, Accounting	Sale	2,038	$14.17	$29K	32,270	Form 4
Feb 2, 2026	Go William Chief Medical Officer	Award	44,000	—	—	44,000	Form 4
Jan 2, 2026	Meyer Andrew Hollman Chief Business Officer	Sale	1,879	$13.73	$26K	83,095	Form 4
Jan 2, 2026	DiRaimondo Thomas Chief Scientific Officer	Award	31,400	—	—	155,825	Form 4
Jan 2, 2026	DiRaimondo Thomas Chief Scientific Officer	Sale	2,505	$13.73	$34K	124,425	Form 4
Jan 2, 2026	Campbell David Alan President and CEO · Director	Award	96,600	—	—	381,582	Form 4
Jan 2, 2026	Campbell David Alan President and CEO · Director	Sale	8,072	$13.73	$111K	284,982	Form 4
Jan 2, 2026	Winter Charles M. Chief Technical Officer	Award	28,600	—	—	106,321	Form 4
Jan 2, 2026	Winter Charles M. Chief Technical Officer	Sale	2,401	$13.73	$33K	77,721	Form 4
Jan 2, 2026	McIver Zachariah Chief Medical Officer	Award	29,000	—	—	52,286	Form 4
Jan 2, 2026	McIver Zachariah Chief Medical Officer	Sale	2,714	$13.73	$37K	23,286	Form 4
Jan 2, 2026	Doyle Janeen Noel Chief Corp. & Bus. Dev. Ofcr	Award	36,000	—	—	80,000	Form 4
Jan 2, 2026	Dobek Maria Vice President, Accounting	Award	18,935	—	—	34,308	Form 4
Jan 2, 2026	Dobek Maria Vice President, Accounting	Sale	1,462	$13.73	$20K	15,373	Form 4
Dec 1, 2025	Meyer Andrew Hollman Chief Business Officer	Option	3,333	$10.59	$35K	88,307	Form 4
Dec 1, 2025	Meyer Andrew Hollman Chief Business Officer	Sale	2,700	$32.85	$89K	85,607	Form 4
Dec 1, 2025	Meyer Andrew Hollman Chief Business Officer	Sale	633	$33.52	$21K	84,974	Form 4
Nov 14, 2025	Meyer Andrew Hollman Chief Business Officer	Option	3,333	$10.59	$35K	88,307	Form 4
Nov 14, 2025	Meyer Andrew Hollman Chief Business Officer	Sale	3,333	$30.00	$100K	84,974	Form 4
Oct 28, 2025	Meyer Andrew Hollman Chief Business Officer	Option	6,666	$10.59	$71K	98,804	Form 4
Oct 28, 2025	Meyer Andrew Hollman Chief Business Officer	Option	9,999	$4.21	$42K	92,138	Form 4
Oct 28, 2025	Meyer Andrew Hollman Chief Business Officer	Sale	16,665	$30.06	$501K	82,139	Form 4
Jun 11, 2025	RA CAPITAL MANAGEMENT, L.P. Director	Award	3,750	—	—	6,250	Form 4
Jun 11, 2025	Barrett Ronald W Director	Award	3,750	—	—	6,250	Form 4

Doyle Janeen Noel

Chief Corp. & Bus. Dev. Ofcr

Sale

Date

Jun 2

4,059

Price

$14.03

Value

$57K

View Form 4 on SEC.gov

Dobek Maria

Vice President, Accounting

Sale

Date

May 11

2,038

Price

$14.17

Value

$29K

View Form 4 on SEC.gov

Go William

Chief Medical Officer

Award

Date

Feb 2

44,000

Price

—

Value

—

View Form 4 on SEC.gov

Meyer Andrew Hollman

Chief Business Officer

Sale

Date

Jan 2

1,879

Price

$13.73

Value

$26K

View Form 4 on SEC.gov

DiRaimondo Thomas

Chief Scientific Officer

Award

Date

Jan 2

31,400

Price

—

Value

—

View Form 4 on SEC.gov

DiRaimondo Thomas

Chief Scientific Officer

Sale

Date

Jan 2

2,505

Price

$13.73

Value

$34K

View Form 4 on SEC.gov

Campbell David Alan

President and CEO · Director

Award

Date

Jan 2

96,600

Price

—

Value

—

View Form 4 on SEC.gov

Campbell David Alan

President and CEO · Director

Sale

Date

Jan 2

8,072

Price

$13.73

Value

$111K

View Form 4 on SEC.gov

Winter Charles M.

Chief Technical Officer

Award

Date

Jan 2

28,600

Price

—

Value

—

View Form 4 on SEC.gov

Winter Charles M.

Chief Technical Officer

Sale

Date

Jan 2

2,401

Price

$13.73

Value

$33K

View Form 4 on SEC.gov

McIver Zachariah

Chief Medical Officer

Award

Date

Jan 2

29,000

Price

—

Value

—

View Form 4 on SEC.gov

McIver Zachariah

Chief Medical Officer

Sale

Date

Jan 2

2,714

Price

$13.73

Value

$37K

View Form 4 on SEC.gov

Doyle Janeen Noel

Chief Corp. & Bus. Dev. Ofcr

Award

Date

Jan 2

36,000

Price

—

Value

—

View Form 4 on SEC.gov

Dobek Maria

Vice President, Accounting

Award

Date

Jan 2

18,935

Price

—

Value

—

View Form 4 on SEC.gov

Dobek Maria

Vice President, Accounting

Sale

Date

Jan 2

1,462

Price

$13.73

Value

$20K

View Form 4 on SEC.gov

Meyer Andrew Hollman

Chief Business Officer

Option

Date

Dec 1

3,333

Price

$10.59

Value

$35K

View Form 4 on SEC.gov

Meyer Andrew Hollman

Chief Business Officer

Sale

Date

Dec 1

2,700

Price

$32.85

Value

$89K

View Form 4 on SEC.gov

Meyer Andrew Hollman

Chief Business Officer

Sale

Date

Dec 1

633

Price

$33.52

Value

$21K

View Form 4 on SEC.gov

Meyer Andrew Hollman

Chief Business Officer

Option

Date

Nov 14

3,333

Price

$10.59

Value

$35K

View Form 4 on SEC.gov

Meyer Andrew Hollman

Chief Business Officer

Sale

Date

Nov 14

3,333

Price

$30.00

Value

$100K

View Form 4 on SEC.gov

Meyer Andrew Hollman

Chief Business Officer

Option

Date

Oct 28

6,666

Price

$10.59

Value

$71K

View Form 4 on SEC.gov

Meyer Andrew Hollman

Chief Business Officer

Option

Date

Oct 28

9,999

Price

$4.21

Value

$42K

View Form 4 on SEC.gov

Meyer Andrew Hollman

Chief Business Officer

Sale

Date

Oct 28

16,665

Price

$30.06

Value

$501K

View Form 4 on SEC.gov

RA CAPITAL MANAGEMENT, L.P.

Director

Award

Date

Jun 11

3,750

Price

—

Value

—

View Form 4 on SEC.gov

Barrett Ronald W

Director

Award

Date

Jun 11

3,750

Price

—

Value

—

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 3

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About JANX insider trading

JANX insider trades

Janux Therapeutics, Inc. (JANX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Meyer Andrew Hollman (Chief Business Officer), Dobek Maria (Vice President, Accounting), Doyle Janeen Noel (Chief Corp. & Bus. Dev. Ofcr). Over the past 12 months, 5 insiders have filed transactions with the SEC. JANX insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Janux Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

JANX insider trading · 5 questions

The insiders of Janux Therapeutics, Inc. (JANX) include executives and directors such as Meyer Andrew Hollman (Chief Business Officer), Dobek Maria (Vice President, Accounting), Doyle Janeen Noel (Chief Corp. & Bus. Dev. Ofcr), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

JANX board member insider tradingwho are JANX insidersJANX insider rosterJanux Therapeutics, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026